Oran Knowlson, now aged 13, has Lennox-Gastaut syndrome, a treatment-resistant form of epilepsy which he developed at the age of three. He was invited to take part in the CADET project, which assessed the safety and effectiveness of the new deep brain stimulation device to control seizures for severe epilepsy.
The Picostim neurotransmitter, used in the project, is made by UK company Amber Therapeutics, whose Director Prof. Timothy Denison is contributing Principal Investigator in the OH BRC Brain Technologies Theme.